Not exact matches
Low
risk was defined as patients with the presence of inv (16) / t (16; 16) or t (8; 21)
cytogenetic features, NPM1 or CEBPA mutations, or MRD < 0.1 % post-induction I in those with no high -
risk features.
«Even high -
risk patients have close to a 70 percent chance of getting to what we call a complete
cytogenetic response, which is an optimal response to the drug,» said Druker.
«And more importantly, we found that if a patient achieves a complete
cytogenetic response, the
risk of relapse is the same whether the patient was at low, medium, or high
risk when diagnosed,» said Druker.
Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorizing patients into
risk groups.